Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation.

Nardelli F, Paissoni C, Quilici G, Gori A, Traversari C, Valentinis B, Sacchi A, Corti A, Curnis F, Ghitti M, Musco G.

J Med Chem. 2018 Jun 26. doi: 10.1021/acs.jmedchem.8b00745. [Epub ahead of print]

PMID:
29883545
2.

A critical assessment of force field accuracy against NMR data for cyclic peptides containing β-amino acids.

Paissoni C, Nardelli F, Zanella S, Curnis F, Belvisi L, Musco G, Ghitti M.

Phys Chem Chem Phys. 2018 Jun 13;20(23):15807-15816. doi: 10.1039/c8cp00234g.

PMID:
29845162
3.

Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.

Elia AR, Grioni M, Basso V, Curnis F, Freschi M, Corti A, Mondino A, Bellone M.

Clin Cancer Res. 2018 May 1;24(9):2171-2181. doi: 10.1158/1078-0432.CCR-17-2210. Epub 2018 Feb 28.

PMID:
29490991
4.

Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Corti A, Gasparri AM, Ghitti M, Sacchi A, Sudati F, Fiocchi M, Buttiglione V, Perani L, Gori A, Valtorta S, Moresco RM, Pastorino F, Ponzoni M, Musco G, Curnis F.

Adv Funct Mater. 2017 Sep 26;27(36). pii: 1701245. doi: 10.1002/adfm.201701245.

5.

T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.

Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, Freschi M, Elia AR, Grioni M, Curnis F, Protti MP, Schumacher TN, Debets R, Swartz MA, Corti A, Bellone M, Mondino A.

Cancer Res. 2017 Feb 1;77(3):658-671. doi: 10.1158/0008-5472.CAN-16-0725. Epub 2016 Nov 21.

6.

Regulation of tumor growth by circulating full-length chromogranin A.

Curnis F, Dallatomasina A, Bianco M, Gasparri A, Sacchi A, Colombo B, Fiocchi M, Perani L, Venturini M, Tacchetti C, Sen S, Borges R, Dondossola E, Esposito A, Mahata SK, Corti A.

Oncotarget. 2016 Nov 8;7(45):72716-72732. doi: 10.18632/oncotarget.12237.

7.

NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors.

Curnis F, Fiocchi M, Sacchi A, Gori A, Gasparri A, Corti A.

Nano Res. 2016 May;9(5):1393-1408. Epub 2016 Mar 4.

8.

Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.

9.

Ceruloplasmin functional changes in Parkinson's disease-cerebrospinal fluid.

Barbariga M, Curnis F, Andolfo A, Zanardi A, Lazzaro M, Conti A, Magnani G, Volontè MA, Ferrari L, Comi G, Corti A, Alessio M.

Mol Neurodegener. 2015 Nov 4;10:59. doi: 10.1186/s13024-015-0055-2.

10.

Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

Cossu I, Bottoni G, Loi M, Emionite L, Bartolini A, Di Paolo D, Brignole C, Piaggio F, Perri P, Sacchi A, Curnis F, Gagliani MC, Bruno S, Marini C, Gori A, Longhi R, Murgia D, Sementa AR, Cilli M, Tacchetti C, Corti A, Sambuceti G, Marchiò S, Ponzoni M, Pastorino F.

Biomaterials. 2015 Nov;68:89-99. doi: 10.1016/j.biomaterials.2015.07.054. Epub 2015 Aug 1.

11.

Oxidation-induced structural changes of ceruloplasmin foster NGR motif deamidation that promotes integrin binding and signaling.

Barbariga M, Curnis F, Spitaleri A, Andolfo A, Zucchelli C, Lazzaro M, Magnani G, Musco G, Corti A, Alessio M.

J Biol Chem. 2014 Feb 7;289(6):3736-48. doi: 10.1074/jbc.M113.520981. Epub 2013 Dec 23.

12.

Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3.

Neubauer S, Rechenmacher F, Beer AJ, Curnis F, Pohle K, D'Alessandria C, Wester HJ, Reuning U, Corti A, Schwaiger M, Kessler H.

Angew Chem Int Ed Engl. 2013 Oct 25;52(44):11656-9. doi: 10.1002/anie.201306376. Epub 2013 Sep 20.

PMID:
24115324
13.

Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.

Corti A, Curnis F, Rossoni G, Marcucci F, Gregorc V.

BioDrugs. 2013 Dec;27(6):591-603. doi: 10.1007/s40259-013-0048-z. Review.

14.

Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.

Loi M, Di Paolo D, Soster M, Brignole C, Bartolini A, Emionite L, Sun J, Becherini P, Curnis F, Petretto A, Sani M, Gori A, Milanese M, Gambini C, Longhi R, Cilli M, Allen TM, Bussolino F, Arap W, Pasqualini R, Corti A, Ponzoni M, Marchiò S, Pastorino F.

J Control Release. 2013 Sep 10;170(2):233-41. doi: 10.1016/j.jconrel.2013.04.029. Epub 2013 May 25.

15.

A new chromogranin A-dependent angiogenic switch activated by thrombin.

Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP, Curnis F, Corti A.

Blood. 2013 Jan 10;121(2):392-402. doi: 10.1182/blood-2012-05-430314. Epub 2012 Nov 27.

16.

IsoDGR-tagged albumin: a new αvβ3 selective carrier for nanodrug delivery to tumors.

Curnis F, Sacchi A, Longhi R, Colombo B, Gasparri A, Corti A.

Small. 2013 Mar 11;9(5):673-8. doi: 10.1002/smll.201202310. Epub 2012 Nov 12.

PMID:
23143930
17.

Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice.

Curnis F, Gasparri AM, Longhi R, Colombo B, D'Alessio S, Pastorino F, Ponzoni M, Corti A.

Cell Mol Life Sci. 2012 Aug;69(16):2791-803. doi: 10.1007/s00018-012-0955-z. Epub 2012 Mar 14.

PMID:
22415324
18.

Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.

Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A, Bellone M.

J Immunol. 2012 Mar 15;188(6):2687-94. doi: 10.4049/jimmunol.1101877. Epub 2012 Feb 8.

19.

Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.

Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A.

Cancer Res. 2011 Sep 1;71(17):5881-90. doi: 10.1158/0008-5472.CAN-11-1273. Epub 2011 Jul 28.

20.

Tumor vasculature targeting through NGR peptide-based drug delivery systems.

Corti A, Curnis F.

Curr Pharm Biotechnol. 2011 Aug;12(8):1128-34. Review.

PMID:
21470145
21.

Targeted drug delivery and penetration into solid tumors.

Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R.

Med Res Rev. 2012 Sep;32(5):1078-91. doi: 10.1002/med.20238. Epub 2011 Feb 1. Review.

PMID:
21287572
22.

Isoaspartate-dependent molecular switches for integrin-ligand recognition.

Corti A, Curnis F.

J Cell Sci. 2011 Feb 15;124(Pt 4):515-22. doi: 10.1242/jcs.077172. Review.

23.

Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.

Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F.

J Control Release. 2010 Jul 1;145(1):66-73. doi: 10.1016/j.jconrel.2010.03.015. Epub 2010 Mar 24.

PMID:
20346382
24.

Role of vasostatin-1 C-terminal region in fibroblast cell adhesion.

Dondossola E, Gasparri A, Bachi A, Longhi R, Metz-Boutigue MH, Tota B, Helle KB, Curnis F, Corti A.

Cell Mol Life Sci. 2010 Jun;67(12):2107-18. doi: 10.1007/s00018-010-0319-5. Epub 2010 Mar 9.

PMID:
20217454
25.

Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, Di Matteo P, Traversari C, Bachi A, Ponzoni M, Rizzardi GP, Corti A.

J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11.

26.

Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.

Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A.

Mol Cancer Ther. 2008 Dec;7(12):3859-66. doi: 10.1158/1535-7163.MCT-08-0538.

27.

Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.

Curnis F, Sacchi A, Gasparri A, Longhi R, Bachi A, Doglioni C, Bordignon C, Traversari C, Rizzardi GP, Corti A.

Cancer Res. 2008 Sep 1;68(17):7073-82. doi: 10.1158/0008-5472.CAN-08-1272.

28.

The neovasculature homing motif NGR: more than meets the eye.

Corti A, Curnis F, Arap W, Pasqualini R.

Blood. 2008 Oct 1;112(7):2628-35. doi: 10.1182/blood-2008-04-150862. Epub 2008 Jun 23. Review.

29.

Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin.

Spitaleri A, Mari S, Curnis F, Traversari C, Longhi R, Bordignon C, Corti A, Rizzardi GP, Musco G.

J Biol Chem. 2008 Jul 11;283(28):19757-68. doi: 10.1074/jbc.M710273200. Epub 2008 May 13.

30.

Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.

Crippa L, Gasparri A, Sacchi A, Ferrero E, Curnis F, Corti A.

Cancer Res. 2008 Feb 15;68(4):1154-61. doi: 10.1158/0008-5472.CAN-07-2085.

31.

Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function.

Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A.

Eur Heart J. 2007 May;28(9):1117-27. Epub 2007 Mar 27.

PMID:
17389654
32.

Spontaneous formation of L-isoaspartate and gain of function in fibronectin.

Curnis F, Longhi R, Crippa L, Cattaneo A, Dondossola E, Bachi A, Corti A.

J Biol Chem. 2006 Nov 24;281(47):36466-76. Epub 2006 Oct 2.

33.

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.

Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A.

Clin Cancer Res. 2006 Jan 1;12(1):175-82.

34.

Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.

Di Matteo P, Curnis F, Longhi R, Colombo G, Sacchi A, Crippa L, Protti MP, Ponzoni M, Toma S, Corti A.

Mol Immunol. 2006 Apr;43(10):1509-18. Epub 2005 Dec 7.

PMID:
16337683
35.

Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.

Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A.

Cancer Res. 2005 Apr 1;65(7):2906-13.

36.
37.

Production and characterization of recombinant human and murine TNF.

Curnis F, Corti A.

Methods Mol Med. 2004;98:9-22.

PMID:
15064429
38.

Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity.

Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A.

Cancer Res. 2004 Jan 15;64(2):565-71.

39.

Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage.

Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, Curnis F, Villa A, Ferrero ME, Corti A.

FASEB J. 2004 Mar;18(3):554-6. Epub 2004 Jan 20.

PMID:
14734634
40.

Regulation of endothelial cell shape and barrier function by chromogranin A.

Ferrero E, Magni E, Curnis F, Villa A, Ferrero ME, Corti A.

Ann N Y Acad Sci. 2002 Oct;971:355-8. Review.

PMID:
12438151
41.

Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.

Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, Sacchi A, Longhi R, Corti A.

J Biol Chem. 2002 Dec 6;277(49):47891-7. Epub 2002 Oct 7.

42.

Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion.

Colombo B, Longhi R, Marinzi C, Magni F, Cattaneo A, Yoo SH, Curnis F, Corti A.

J Biol Chem. 2002 Nov 29;277(48):45911-9. Epub 2002 Sep 23.

43.
44.

Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models.

Colombo B, Curnis F, Foglieni C, Monno A, Arrigoni G, Corti A.

Cancer Res. 2002 Feb 1;62(3):941-6.

45.

Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.

Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A.

Cancer Res. 2002 Feb 1;62(3):867-74.

46.

Biotinylation sites of tumor necrosis factor-alpha determined by liquid chromatography-mass spectrometry.

Magni F, Curnis F, Marazzini L, Colombo R, Sacchi A, Corti A, Kienle MG.

Anal Biochem. 2001 Nov 15;298(2):181-8.

PMID:
11700972
47.

Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability.

Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A.

Am J Physiol Cell Physiol. 2001 Oct;281(4):C1173-9.

48.

Caspase inhibition reveals functional cooperation between p55- and p75-TNF receptors in cell necrosis.

Pelagi M, Curnis F, Colombo B, Rovere P, Sacchi A, Manfredi AA, Corti A.

Eur Cytokine Netw. 2000 Dec;11(4):580-8.

49.

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A.

Nat Biotechnol. 2000 Nov;18(11):1185-90.

PMID:
11062439
50.

Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells.

Ratti S, Curnis F, Longhi R, Colombo B, Gasparri A, Magni F, Manera E, Metz-Boutigue MH, Corti A.

J Biol Chem. 2000 Sep 22;275(38):29257-63.

Supplemental Content

Loading ...
Support Center